VT News
Lio Tipton

Lio Tipton

Ask VT AI
View News Summary
  • DaVita's Q3 earnings miss expectations, with lower dialysis treatments and higher costs, leading to narrowed guidance and stock decline.
  • Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges.
  • Novo Nordisk challenges Pfizer's acquisition of Metsera with a $6.5 billion bid, sparking a high-stakes contest for obesity and GLP-1 assets.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • DaVita's Q3 earnings miss expectations, with lower dialysis treatments and higher costs, leading to narrowed guidance and stock decline.
  • Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges.
  • Novo Nordisk challenges Pfizer's acquisition of Metsera with a $6.5 billion bid, sparking a high-stakes contest for obesity and GLP-1 assets.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Lio Tipton

Top Topics

Trending in U.S.

World

Sport